In this studyw we characterize the connections between p53-dependent G1 cell cycle arrest, transcriptional activation of the protein and the increase of its intracellular steady-state concentration. Several cell lines expressing wild-type p53 protein were treated with increasing concentrations of DNA-damaging drug camptothecin. Lower doses of the drug caused transcriptional activation of p53, but no accumulation of the protein was detected. Only after a certain threshold dose of camptothecin does the amount of the protein rapidly increase and reach its plateau levels. The threshold dose was dierent for dierent cell lines, but the general nonlinear pro®le was similar. Increase of p53 level was accompanied by additional transcriptional activation of some p53 target genes (i.e. waf1), but not the others (mdm2). We demonstrate here that transcriptional activation of p53 after the treatment of camptothecin is not sucient to cause p53-dependent G1 cell cycle arrest. The latter is observable only after the inrease of steady-state level of p53. Low drug concentrations, although accompanied by transcriptional activation of p53, do not cause either p53 protein accumulation nor cell cycle arrest at G1. We propose a model for p53 acting as a part of cellular sensor system detecting the severity of DNA damage. Oncogene (2001) 20, 1212 ± 1219.
Introduction
The p53 tumor suppressor protein is a critical regulator of cell cycle progression and apoptosis following exposure of cells to DNA damage. Accumulation of p53 has been described in response to ionizing radiation (Kastan et al., 1991) , ultraviolet irradiation (Maltzman and Czyzyk, 1984; Nelson and Kastan, 1994) , hypoxia (Graeber et al., 1994) and several other eectors. The upregulation of the tumor suppressor gene product is mediated both by its enhanced translation (Fu et al., 1996) and prolonged half-life (Maltzmann and Czyzyk, 1984) . As a consequence, cells stop dividing (Kastan et al., 1991) and may die apoptotically (Lowe et al., 1993) . This avoids the multiplication of cells with damaged DNA and justi®ed the description of p53 as the`guardian of the genome' (Lane, 1992) .
The best-studied function of p53 is that of a transcription factor and its accumulation is indeed accompanied by an increase in p53 transcriptional activity (El-Deiry et al., 1993; Kastan, 1993; Kastan et al., 1991; Zhang et al., 1994) . Several post-translational modi®cations of the protein are involved in this process (see May and May, 1999; Lakin and Jackson, 1999 for recent reviews). When activated, p53 can bind sequence-speci®cally to DNA and activate transcription from promoters near by. Waf1, gadd45, mdm2, cyclin G, bax and many others have been described as p53 target genes and p53 mediates its antiproliferative eect mainly through them. Waf1 blocks the activity of CDKs (Dulic et al., 1994; El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) thus preventing the entry of cells into S phase. Waf1 also binds to the proliferating cell nuclear antigen (PCNA) blocking its activity and therefore inhibiting the elongation step in DNA replication , while permitting active DNA repair (Li et al., 1994) . Gadd45 gene product modulates the accessibility of damaged chromatin (Carrier et al., 1999; Kastan et al., 1992) . Bax (Han et al., 1996; Miyashita et al., 1994; Selvakumaran et al., 1994) and cyclin G were found to have a role in p53-dependent apoptosis (Okamoto and Beach, 1994; Okamoto and Prives, 1999) .
p53 is a direct transcriptional activator of mdm2 gene (Barak et al., 1993; Perry et al., 1993) . Mdm2 complexes with p53 thereby inhibiting its transactivation properties and targeting p53 to the proteasomemediated degradation (Haupt et al., 1997; Kubbutat et al., 1997; Momand et al., 1992; Oliner et al., 1992; Wu et al., 1993) . This feedback loop ensures the short-term nature of p53 induction, allowing cells to continue the cycling after repairing their DNA.
Although the choice between the cell cycle arrest and apoptosis after p53 induction depends on additional factors (Canman et al., 1995) or cellular context (Di Leonardo et al., 1994; Radford, 1994) , an important determinant of the outcome can also be the steadystate level of p53 protein. SAOS2 cells stop dividing, when p53 is expressed at moderate levels, but die in the case of high protein expression (Chen et al., 1996) .
We have recently shown that the ability of p53 to activate transcription depends on its concentration. In model systems, lower concentrations of p53 lead to activation of a promoter containing the consensus DNA binding site and higher concentrations to the loss of this activity (Kristjuhan and Maimets, 1995) . We also showed that oligomerization is necessary for this self-inhibition' of transactivation by p53 (Kristjuhan et al., 1998) . Such a phenomenon has also been described in vivo in cell lines where increase of endogenous p53 was induced with ultraviolet irradiation (Lu et al., 1996) . This led us to the hypothesis that intracellular p53 concentration resulting from dierent levels of genotoxic stress is an important determinant of cellular behavior in response to DNA damage.
In this paper we show that transcriptional activation of p53 occurring after treatment of cells with DNA damaging agent camptothecin is not sucient to cause p53-dependent G1 cell cycle arrest. The latter is observable only after the increase of steady-state level of p53 in cells, which is caused by higher concentrations of the drug. Lower concentrations of the drug, although accompanied with transcriptional activation of p53, do not cause p53 protein accumulation and p53-dependent cell cycle arrest. Our results allow us to propose a model for p53 acting as a part of a cellular sensor system for the severity of DNA damage.
Results

Cellular accumulation of p53 protein is detectable only at higher concentrations of camptothecin
In normal cells and most cell lines containing wild-type p53 the damage of DNA induces accumulation of p53 protein (Deptala et al,. 1999; Nelson and Kastan, 1994) . Camptothecin (CPT), a well-known drug for tumor therapy, has been used as a DNA-damaging agent in several experiemental systems. CPT traps DNA topoisomerase I into so-called`cleavable complexes' and creates DNA strand breaks (Avemann et al., 1988; Ryan et al., 1991) .
We studied the steady-state levels of p53 protein after the treatment of several cell lines with dierent concentrations of CPT. Human (MCF7, LoVo) and murine (NIH3T3, C127) cells containing wild-type p53 all responded to the increasing concentrations of CPT with the non-linear increase of p53 levels (Figure 1 ). Lower doses of CPT do not cause the increase of p53 level in cells. Only after a certain threshold dose of CPT (which can be de®ned as minimal concentration of CPT needed to induce the increase of p53 protein) the accumulation of p53 is evident and it quickly reaches its plateau levels. This threshold level of the drug is clearly dierent in the dierent cells studied. In MCF7 and LoVo cells the accumulation of p53 protein is visible already at CPT concentrations 0.01 and 0.03 mM respectively, whereas much higher concentrations of the drug are needed to see similar response at p53 levels in NIH3T3 and C127 cells. In the latter cases CPT doses of 1 mM and higher are needed to increase the p53 level (Figure 1 ). Further increase of CPT concentration above the threshold level does not cause any further increase of cellular p53 level. Therefore, although the threshold CPT concentration for dierent cell lines can dier more than a hundred times, the general pro®le of cellular response is the same: no p53 accumulation at low CPT doses and rapid increase of the protein concentration at the doses above the threshold level of the drug. p53 transcriptional activity is induced at both high and low concentrations of camptothecin p53 must be transcriptionally active to suppress the cell growth after the DNA damage (Chao et al., 2000) . Genotoxic stress induces both accumulation of p53 protein and its transcriptional activation, whereas the two events are independent: transcriptional activation of p53 can occur without accumulation of the protein (Chernov et al., 1998; HaapajaÈ rvi et al., 1997) .
We next studied, whether the low levels of CPT incompetent to induce the increase of p53 protein, still activate the transcriptional functions of p53. NIH3T3 cells were treated with low (no p53 accumulation), medium (near the threshold level) and high (extensive p53 accumulation) doses of CPT. Ribonuclease Protection analyses indicate that p53-dependent transcriptional activation can be seen already at low doses of CPT ( Figure 2 ). p53-dependent genes cyclin G, mdm2, gadd45 and waf1 are all activated already at subthreshold doses of CPT, where no increase of p53 level is present (compare Figures 1 and 2 ). At higher doses of the drug some genes (like waf1) are further activated, whereas others (like mdm2) are activated at the same level both at low and high concentrations of Similar pattern of p53 target gene activation is evident also in other p53 positive cell lines (Figure 3 ). Both cyclin G and waf1 mRNA-s are elevated at doses of CPT which are below the threshold for p53 protein accumulation.
p53 is able to block the cell cycle only when accumulated in the cell
The major cellular outcomes of cellular growth pathways regulated by p53 are cell cycle arrest and apoptosis (Lowe et al., 1993; Shaw et al., 1992) . Our results presented above (and these of others) show that the transcriptional activity and steady-state level of p53 protein are regulated independently. Recent experiments have shown that transcriptional activation is indispensable for tumor suppression function of p53 (Chao et al., 2000; Jimenez et al., 2000) . We therefore studied next the eects of p53 transcriptional activation and increase of its steady-state level to the cell cycle control.
The cells were treated for 24 h with dierent concentrations of CPT and cell distribution of the cells and their BrdU incorporation pro®les (labeled for the last hour during the CPT-treatment) were analysed. The results described in Figures 4 and 5 show that cell lines expressing wild-type p53 block their cell cycle at G1 only when the doses of CPT exceeding the threshold level for p53 accumulation are used. In MCF7 cells the protein accumulates at 0.15 mM CPT and the cells exhibit G1 arrest and DNA synthesis block only at CPT concentrations above this level. In the case of NIH3T3 and C127 much higher concentrations of CPT are needed to induce the G1 arrest (4 mM), which correspond to the concentration of the drug needed for accumulation of p53 protein (see Figure 1 ). At the same CPT concentration the DNA synthesis is also blocked, whereas treatment with 0.3 mM CPT is neither able to block the cells in G1 nor inhibit the DNA synthesis. Wt p53-negative cell lines 10(1), C33A (Figures 4 and 5) and SAOS2 (data not shown) continue the DNA synthesis even after treatment with high doses of CPT. These results clearly show that although p53 is transcriptionally activated at low doses of CPT, the high levels of the protein are required to block the cell cycle in G1 phase.
CPT also arrests the cells at G2 phase of the cell cycle, whereas this event is independent of their p53 status. The p53-negative cells exhibit this type of G2 arrest at all CPT concentrations used (Figures 4 and 5) . At low CPT concentrations p53-positive cells also arrest in G2, showing that p53 does not possess cell cycle blocking activity if lower than threshold amounts of CPT are used. Similar p53-independent cell cycle block has also been described earlier as a result of girradiation and Actinomycin D treatment of the cells (Kastan et al., 1991) .
It must be mentioned that LoVo cells did not exhibit G1 arrest of the cell cycle at any doses of the drug Cells were treated with indicated amounts of CPT, total RNA was isolated after 4 h and analysed by Northern blotting. The ®lters were probed with human waf1 cDNA or with part of the murine cyclin G cDNA. To assess RNA loading either electrophoresis gels were stained with ethidium bromide to visualize ribosomal RNA (rRNA) or ®lters were stripped and reprobed with mouse b-actin cDNA probe Differential p53 responses V Jaks et al tested, therefore resembling the wt p53-negative cell lines 10(1) and C33A (Figures 4 and 5 ). This may be explained by the destruction of cell cycle blocking pathway in these cells. In wt p53-de®cient SAOS2 cell line we also observed accumulation of cells in subpopulation with DNA content similar to the 2N after their treatment with CPT. Serum starvation experiments showed that this was not due to G1 arrest but rather accumulation of cells in early S phase (data not shown).
Discussion
Multicellular organisms must keep the growth of their cells under control and avoid multiplication of cells with damaged DNA. In many organisms p53 is one of the central players in these pathways. It can initiate cell cycle block and/or apoptosis in response to DNA damage and therefore avoid accumulation of cells with potentially mutated DNA. On the other hand, inhibition of normal cellular activities by reacting too sensitively to minor DNA lesions can also have negative eects on the organism. It is therefore reasonable to assume that the cells would try to counteract the low amount of DNA damage without stopping the cell cycle. In this paper we describe experimental evidence for this assumption. Two human and three mouse cell lines expressing wild-type p53 were treated with dierent doses of camptothecin (CTP), a powerful inhibitor of topoisomerase I causing DNA strand breaks and therefore serving as an inducer of p53 activity and its accumulation. All cell lines exhibited the same pro®le of p53 accumulation as a response to CPT treatment. At low doses of the drug no increase of p53 steadystate level was seen, whereas the higher cncentrations of the drug induced rapid accumulation of the protein.
The threshold level for CPT concentration needed to induce p53 protein was dierent for the cell lines studied. This dierence can be explained either by their dierences in susceptibility to DNA damage (e.g. dierent levels of DNA reparation activities) or by their dierent properties related to the drug (e.g. dierent membrane pumps, anity of topoisomerase I to CPT etc.).
Once induced, the levels of p53 protein rapidly achieve its maximum and further increase of CPT concentration does not elevate the amount of protein further. Therefore, the accumulation of p53 protein after CPT treatment is either switched`on' or`o', which in turn depends on the threshold level of CPT.
Low levels of DNA damage do not induce accumulation of the protein, although the protein becomes transcriptionally active. However, no p53- speci®c eects to the cell cycle regulation and rate of DNA synthesis can be observed after treatment of cells with low levels of CPT. Therefore, mere activation of p53-dependent transcription is not sucient to induce G1 arrest or abrogation of DNA synthesis. High levels of DNA damage, which induce accumulation of p53 protein, evoke G1 cell cycle arrest and block o DNA synthesis in p53-positive but not in p53-negative cells. Transcription from some p53-dependent promoters achieved maximum level already at low doses of CPT, whereas other promoters were further activated with high doses of CPT. This suggests that p53 protein accumulation de novo after high doses of CPT can have dierent properties compared to transcriptionally active p53, which is expressed at low levels after treatment with sub-threshold doses of CPT. Dierently modi®ed subpopulations, which can coexist in the cells (Maxwell et al., 1996; Selkirk et al., 1996) , can also have dierent promoter selectivity. Stabilized p53 protein can also have qualities, which are dierent from its transactivation function. p53 can stabilize waf1 mRNA after DNA damage (Gorospe et al., 1998) . Also, the translation of CDK4 mRNA is repressed in wt p53 dependent manner (Ewen, 1996) .
Activation of p53 at low doses of CPT can also include other activities dierent from its transactivation function. Wild-type p53 is involved both in nucleotide excision repair (NER) and base excision repair (BER). After low-level DNA damage the main activity of p53 can be connected with these pathways. Indeed, low levels of DNA damage can stimulate DNA repair in p53-positive, but not in p53-negative cells (Li and Ho, 1998; Oer et al., 1999) . In the case of high-level DNA damage, however, neither of the cell lines shows any enhancement of DNA repair (Dr Varda Rotter, personal communication; Li and Ho, 1998) .
Taking together these data we propose a model according to which the level of p53 protein is a major determinant of cell's response to DNA damage ( Figure  6 ). According to this model, the accumulation of p53 is a signal for the cell about levels of DNA damage exceeding its repair capabilites. This leads to abrogation of DNA synthesis and evokes cell cycle arrest at G1/S and S phases.
How p53 (or its modulators) exactly diers between low and high levels of DNA damage remains to be clari®ed. There are several proteins, which recognize and bind to DNA lesions in the cell. Signals about DNA damage are transferred to p53 by ATM/ATR and Chk1/Chk2 pathways (Shieh et al., 2000) . It will be Figure 6 Model of cell cycle regulation in response to dierent levels of DNA damage. Cellular sensing systems can detect the DNA damage and transform the dierent signals according to its severity. p53 is involved in both pathways, but its activity depends on the extent of DNA damage. In the case of low DNA damage, p53 gets activated, but no accumulation of the protein or G1 arrest follows. If the extent of DNA damage exceeds a certain threshold, the p53-dependent G1 arrest follows. Cells lacking wt p53 are unable to respond to any DNA damage signal and continue their cycle important to see, whether any of these mechanisms is involved in switching on the accumulation of p53 protein.
High levels of the protein may be needed for direct inhibition of ongoing replication (Cox et al., 1995) .
Materials and methods
Cell culture and camptothecin treatment
Human cell lines MCF7, LoVo, C33A and mouse cell lines C127, NIH3T3 and 10(1) (a generous gift from Arnold Levine) were maintained in Iscove's modi®ed Dulbecco's medium (IMDM ± Sigma-Aldrich Co., St. Louis, MO, USA) containing 10% fetal calf serum (FCS ± Gibco Life Technologies, UK) at 378C. Camptothecin (Sigma-Aldrich Co., St. Louis, MO, USA) was dissolved in DMSO at 10 mM concentration and added directly to the growth media. For negative control, cells were mock-treated with 5 ml of DMSO in 10 ml of growth media.
Template set preparation for ribonuclease protection assay
Total RNA was extracted from 10(1) cells using RNeasy kit (Qiagen GmbH, Hilden, Germany). This was used as a template for ®rst strand reaction using Moloney Murine Leukemia Virus reverse transcriptase (Amersham Pharmacia Biotech AB, Uppsala, Sweden). The reaction was performed as recommended by enzyme supplier. Brie¯y, 10 mg total RNA, 10 ml ®rst strand buer (56), 2.5 ml dNTP mix (10 mM each), 5 ml oligo(dT), 2 ml ribonuclease inhibitor (25 U/ml) and 18 ml sterile RNase-free water were mixed on ice. Reaction was initiated by adding 200 units of MMLV reverse transcriptase and incubated for 1 h. Synthesized DNA was extracted using phenol extraction. This was used as template for PCR. As a result short DNA fragments corresponding to 3'-regions of four p53 response genes and GAPDH were generated. Restriction endonuclease recognition sites were included in PCR primers to facilitate following subcloning. The sequence of used PCR primers along with the lengths of ampli®ed cDNA fragments and restriction endonuclease recognition sites are as follows: (a) waf1, probe length 320 bp, forward: (XbaI) 5'-GCTCTAGACGGA-GACGCCGCTGGAGGGCAACTTCG-3' reverse: (BamHI) 5'-CGGGATCCTCAGGGTTTTCTCTTGCAGAAGACC-3' (b) mdm2, probe length 300 bp, forward: (EcoRI) 5'-CGG-AATTCGACGACTATTCCCAACCATCGACTTCC-3' reverse: (KpnI) 5'-GGGGTACCCTAGTTGAAGTAAGTTA-GCACAATC-3' (c) gadd45, probe length 280 bp, forward: (XbaI) 5'-GCTCTAGACCATTTCA-CCCTCATCCGTGC-GTTC-3' reverse: (KpnI) 5'-GGGGTACCTCACCGTTCC-GGGAGATTAATCACG-3' (d) cyclin G, probe length 260 bp, forward: (XbaI) 5'-GCT CTAGATGGAGATCCA-AGCACTGAAATACGTAG-3' reverse: (BamHI) 5'-CGGG-ATCCCTAACA-AATGGTCTCAGGAATCGTTGG-3' (e) GAPDH, probe length 160 bp, forward: (XbaI) 5'-CGTCTA-GAGCGACTTCAACAGCAACTCCCAC-3' reverse: (Bg1II) 5'-GCAGATCTTTACTCCTTGGAGGCCATGTAG-3'. PCR-ampli®ed fragments were subcloned into pBluescript SK (+) vector so that T7 polymerase transcription generated antisense mRNA fragments. Inserts were checked by direct sequencing. One mg of each plasmid was linearized using XbaI. Equal transcription of all probes was con®rmed in separate in vitro transcription assays followed by quantitation of transcripts as described below. For template set equal amounts (1 mg) of each linearized plasmid were mixed in 10 ml TE.
Ribonuclease protection assay
To analyse the mRNA level of four p53 target genes and GAPDH RiboQuant (BD PharMingen, San Diego, CA, USA) ribonuclease protection assay (RPA) kit was used. All procedures were carried out as suggested by the manufacturer with minor modi®cations. Brie¯y, cells were washed twice with PBS and RNA extraction was performed using RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) as indicated by the manufacturer. RNA was stored in RNase-free water at 7708C until use.
For probe synthesis 1 ml RNase inhibitor (30 m/ml, Fermentas AB, Vilnius, Lithuania), 1 ml GACU pool (GAC 2.75 mM each, U 61 mM), 2 ml DTT (100 mM), 4 ml 56 transcription buer, 1 ml template set, 10 ml [a-32 P]UTP and 1 ml T7 RNA polymerase (20 u/ml, Fermentas AB, Vilnius, Lithuania) were mixed and incubated for 1 h at 378C. To digest DNA template 2 ml of RNase-free DNase I were added and incubated for 30 min. RNA probes were extracted using RNeasy kit (Qiagen, Hilden, Germany), precipitated with ethanol and dissolved in hybridization buer provided in RiboQuant kit to approximately 3610 5 c.p.m./ml. Two mg of total RNA was dried in vacuum evaporator, dissolved in hybridization buer and mixed with 32 P-labeled anti-sense probe mixture from the previous step. Hybridizations of mRNA and antisense probes was carried out at 568C overnight under mineral oil layer. This was followed by RNase A and T1 digestion for 45 min at 308C. RNases were inactivated by proteinase K digestion in the presence of yeast tRNA for 15 min at 378C. RNA was extracted by phenolchloroform extraction, ethanol precipitated for 30 min at 7708C and dissolved in gel loading buer. Samples were resolved by denaturing (8 M urea) 5% polyacrylamide gel electrophoresis. The gel was ®xed in 10% ethanol, dried and subjected to imaging using Phosphorimager and ImageQuaNT software (Molecular Dynamics, Amersham Pharmacia Biotech).
GAPDH mRNA was used as internal control. The values of mRNA levels of p53 target genes were divided by the GADPH mRNA value of the same sample.
Western blot
Cells were washed twice with PBS and lysed in Laemmli sample buer (62 mM TrisCl (pH 6.8); 10% glycerol; 2% SDS; 5% b-mercaptoethanol, 0.003% bromophenol blue). Proteins were separated by SDS-polyacrylamide gel electrophoresis. Proteins were transferred to PVDF membrane (BioBlot PVDF, Corning Costar Corporation, Cambridge, MA, USA) and probed with monoclonal antibody pAb 240 against p53. Equivalent protein loading per lane was veri®ed by probing the membranes with monoclonal antibody C-4 against actin (Roche Diagnostics GmbH, Mannheim, Germany).
This was followed by incubation with biotinylated antimouse IgG antibody (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and streptavidin-alkaline phosphatase or streptavidin-peroxydase conjugates (Amersham Pharmacia Biotech AB, Uppsala, Sweden). Signal was detected using BCIP/NBT staining or enhanced chemiluminescence (ECL+, Amersham Pharmacia Biotech AB, Uppsala, Sweden) as indicated by the manufacturer.
Cell cycle distribution analysis
For cell cycle distribution analysis both attached and¯oating cells were harvested and ®xed in ice-cold 70% ethanol overnight. Fixed cells were pelleted and stained with PBS containing propidium iodide (10 mg/ml) and RNase (0.1 mg/ ml).
Stained cells were subjected to analysis on FACScan¯ow cytometer using CellQuest software (BD Biosciences, Franklin Lakes, USA).
BrdU incorporation assay
For BrdU labeling In Situ Cell Proliferation Kit (Roche Diagnostics GmbH, Mannheim, Germany) was used. All procedures were carried out as suggested by the manufacturer. Brie¯y, 1/10 volume of BrdU labeling solution was added to the growth media (®nal BrdU concentration 10 mM). Cells were incubated with BrdU for 1 h. Attached and¯o ating cells were harvested and ®xed in 70% ethanol containing 15 mM glycine for 30 min at 48C. For DNA denaturation cells were incubated in 4 M HC1 for 15 min at room temperature followed by incubation with PBS to establish pH 6.5. Then the cells were incubated with antiBrdU-FLUOS antibody for 45 min at 378C in a humid chamber and analysed on FACScan¯ow cytometer.
